Net profit of Lincoln Pharmaceuticals rose 48.09% to Rs 18.60 crore in the quarter ended March 2024 as against Rs 12.56 crore during the previous quarter ended March 2023. Sales rose 26.70% to Rs 142.49 crore in the quarter ended March 2024 as against Rs 112.46 crore during the previous quarter ended March 2023.For the full year,net profit rose 27.98% to Rs 93.30 crore in the year ended March 2024 as against Rs 72.90 crore during the previous year ended March 2023. Sales rose 13.76% to Rs 580.55 crore in the year ended March 2024 as against Rs 510.31 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales142.49112.46 27 580.55510.31 14 OPM %12.9014.80 -17.2117.48 - PBDT24.9019.39 28 132.87109.65 21 PBT22.2216.98 31 122.24100.48 22 NP18.6012.56 48 93.3072.90 28 Powered by Capital Market - Live News

Lincoln Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 16 May 2024, has recommended a Final dividend of Rs.1.80 per share (i.e.18%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 May 2024Powered by Capital Market - Live News

Net profit of Lincoln Pharmaceuticals rose 29.75% to Rs 28.04 crore in the quarter ended December 2023 as against Rs 21.61 crore during the previous quarter ended December 2022. Sales rose 9.48% to Rs 146.45 crore in the quarter ended December 2023 as against Rs 133.77 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales146.45133.77 9 OPM %20.2520.00 - PBDT40.5232.78 24 PBT37.7130.51 24 NP28.0421.61 30 Powered by Capital Market - Live News

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 February 2024.Powered by Capital Market - Live News